Expression of Teratocarcinoma-derived Growth Factor-1 (TDGF-1) in Testis Germ Cell Tumors and Its Effects on Growth and Differentiation of Embryonal Carcinoma Cell Line NTERA2/D1
Overview
Authors
Affiliations
The teratocarcinoma-derived growth factor-1 (TDGF-1) gene codes for a 188-aminoacid glycoprotein that shares structural homology with the epidermal growth factor (EGF) family of growth factors. TDGF-1 is highly expressed in the undifferentiated embryonal carcinoma stem cell line NTERA2 clone D1 (NT2/D1) and its expression is downregulated in response to differentiating agents such as retinoic acid (RA) and hexamethylen-bisacetamide (HMBA). To assess the role of TDGF-1 in the onset and/or progression of human germ cell tumors, we analysed TDGF-1 expression by Northern blot and immunostaining in a panel of 59 human germ cell tumors of different histological origins. We show that TDGF-1 expression is markedly elevated in a subset of human testicular germ cell tumors as compared to normal testes. TDGF-1 overexpression occurs in about 100% of tumors with non-seminomatous phenotype, such as embryonal carcinomas and malignant undifferentiated teratocarcinomas. To address the questions of how TDGF-1 (previously called CRIPTO) may affect the growth and/or the differentiation of embryonal carcinoma cells, we have characterized the effects of exogenous recombinant TDGF-1 protein on the proliferation rate and differentiation 'potential of NT2/D1. Exogenous TDGF-1 protein stimulated DNA synthesis and cell proliferation in both undifferentiated and differentiated NT2/D1 cells. However, TDGF-1 protein treatment was unable to block differentiation induced by both RA and HMBA. These results suggest that TDGF-1 growth factor may represent an autocrine growth factor that may be involved in the process of development of testicular neoplasms.
Cuttitta F, Garcia-Sanmartin J, Feng Y, Sunday M, Kim Y, Martinez A Cancers (Basel). 2024; 16(21).
PMID: 39518018 PMC: 11545644. DOI: 10.3390/cancers16213577.
Yao X, Zhou H, Duan C, Wu X, Li B, Liu H Front Immunol. 2023; 13:1096494.
PMID: 36713456 PMC: 9883017. DOI: 10.3389/fimmu.2022.1096494.
Cripto-1 as a Potential Target of Cancer Stem Cells for Immunotherapy.
Ishii H, Afify S, Hassan G, Salomon D, Seno M Cancers (Basel). 2021; 13(10).
PMID: 34065315 PMC: 8160785. DOI: 10.3390/cancers13102491.
Harpelunde Poulsen K, Nielsen J, Gronkaer Toft B, Joensen U, Rasmussen L, Blomberg Jensen M BMC Cancer. 2020; 20(1):349.
PMID: 32326899 PMC: 7181506. DOI: 10.1186/s12885-020-06820-6.
Spiller C, Lobo J, Boellaard W, Gillis A, Bowles J, Looijenga L Cancers (Basel). 2020; 12(3).
PMID: 32210110 PMC: 7140045. DOI: 10.3390/cancers12030760.